Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06300216

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Qilu Hospital of Shandong University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.

Conditions

Interventions

TypeNameDescription
DRUGOctreotide microspheres20mg/30mg Q4W

Timeline

Start date
2024-03-26
Primary completion
2027-11-26
Completion
2028-05-26
First posted
2024-03-08
Last updated
2024-03-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06300216. Inclusion in this directory is not an endorsement.

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors (NCT06300216) · Clinical Trials Directory